# | ||||
---|---|---|---|---|
1 | INFANTLEUKEMIA GENOMIC, CELLULAR AND DEVELOPMENTAL RECONSTRUCTION OFINFANT MLL-AF4+ ACUTE LYMPHOBLASTIC LEUKEMIA | 2016 | 2˙000˙000.00 | 2˙000˙000.00 |
2 | INTHEMLLRBALL Innovative Therapeutic Strategies for Mixed Lineage Leukemia-rearranged B-cell Acute Lymphoblastic Leukemia | 2018 | 158˙121.00 | 158˙121.00 |
3 | HIFLICS Acute Myeloid Leukemia Leukemic Initiating Cells: Contribution of hypoxia/HIF pathway to chemoresistance and relapse | 2019 | 158˙121.00 | 158˙121.00 |
4 | IT4B-ALL Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia | 2019 | 150˙000.00 | 150˙000.00 |
The Institution FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS has been involved also in the following Horizon 2020 projects.